IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals
December 11, 2017

IOTA scientists review the impact of phenotypic profiling in GBM drug discovery and patient stratification

IOTA scientists Dr David Bailey and Dr Fredrik Svensson review recent developments in phenotypic screening techniques with potential clinical applications in treating GBM. Read the paper here.